-
Company Insights
New![]()
Innovation and Patenting activity of Aker BioMarine AS Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Aker BioMarine AS Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
New![]()
Innovation and Patenting activity of BioMarin Pharmaceutical Inc Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of BioMarin Pharmaceutical Inc Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Net Present Value Model: BioMarin Pharmaceutical Inc’s Tralesinidase alfa
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMN-331 in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BMN-331 in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drug Details: BMN-331 is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMN-255 in Primary Hyperoxaluria Type I
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BMN-255 in Primary Hyperoxaluria Type I Drug Details: BMN-255 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – B-4T2001 in Metastatic Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. B-4T2001 in Metastatic Breast Cancer Drug Details: B4T2-001 is under development for the treatment of...
-
Sector Analysis
![]()
Batten Disease (BD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Batten Disease (BD) Marketed and Pipeline Drugs Report Overview Batten disease is also known as neuronal ceroid lipofuscinosis (NCL) and refers to a cluster of hereditary nervous system disorders that typically manifest in childhood. The diverse forms of the disease are categorized based on the gene responsible for the disorder. Due to the varying gene mutations that can cause the disease, the severity of symptoms and their progression rates differ. Symptoms typically include progressive vision loss leading to blindness, seizures,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Metastatic Colorectal Cancer Drug Details: Voyager-V1 is under development for the treatment of...
-
Track & Monitor
![]()
Cell & gene therapy in pharma: recombinant AAV gene therapy
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s recombinant AAV gene therapy within Cell & gene therapy innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned...
-
Track & Monitor
![]()
Cell & gene therapy in pharma: vascular disorder gene therapies
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s vascular disorder gene therapies within Cell & gene therapy innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.